{"id":603158,"date":"2024-05-31T21:03:21","date_gmt":"2024-06-01T01:03:21","guid":{"rendered":"https:\/\/platohealth.ai\/emas-chmp-recommends-new-indications-for-dupixent-skyrizi\/"},"modified":"2024-06-01T10:45:28","modified_gmt":"2024-06-01T14:45:28","slug":"emas-chmp-recommends-new-indications-for-dupixent-skyrizi","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/emas-chmp-recommends-new-indications-for-dupixent-skyrizi\/","title":{"rendered":"EMA\u2019s CHMP recommends new indications for Dupixent, Skyrizi","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

DATA GRAPHICS | Data Byte<\/p>\n

\n
\n
\n

May decisions also include CStone\u2019s PD-1 inhibitor and Pfizer\u2019s Factor IX gene therapy<\/h2>\n

\n By Gunjan Ohri, Data Content Analyst <\/span><\/span>\n<\/p>\n

June 1, 2024 1:03 AM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/span><\/span><\/div>\n

EMA\u2019s CHMP recommended approval of seven new medicines and label expansions for six, including new indications for Dupixent and Skyrizi. <\/p>\n

In May\u2019s review meeting, the committee issued a positive opinion on approval of Dupixent dupilumab<\/span><\/span> from Sanofi<\/a> <\/b>(Euronext:SAN; NASDAQ:SNY) as an add-on therapy for chronic obstructive <\/span>pulmonary disease, a large indication that would help scale Dupixent\u2019s sales, a priority<\/a> of Sanofi CEO Paul Hudson. <\/span>…<\/p>\n